Retention processed placental membrane versus standard of care in treating diabetic foot ulcers
International Wound Journal · 2024
DOI: 10.1111/iwj.70096 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Wound Journal, 2024. Verfasst von Robert G Frykberg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Open Wound Research, Puyallup, Washington, USA. Hauptthemen laut MEDLINE: Diabetic Foot, Standard of Care, Wound Healing. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BioStem Technologies.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Diabetic foot ulcers (DFUs) are a severe complication for diabetic patients, significantly impacting patient quality of life and healthcare system efficiency. Traditional standard of care (SOC) treatments are inadequate for many patients, necessitating the use of advanced wound care products, such as human placental membranes. We studied a real‐world population of large, hard‐to‐heal and complicated wounds, otherwise under‐studied in the wound care literature. To this end, we conducted a retrospective cohort analysis to compare the effectiveness of a human placental amnion/chorion membrane product using retention‐based processing (RE‐AC) and SOC in managing chronic DFUs. During the study period of September 2021 through April 2024, we collected retrospective observational data from electronic health records of 21 patients treated with RE‐AC at three outpatient wound care centres. Additionally, 21 control SOC patients were matched from a wound registry using Coarsened Exact Matching. Patients were categorized into two cohorts based on whether they received RE‐AC or SOC. Key metrics included wound size progression and wound closure. The analysis employed Bayesian regression and Hurdle Gamma Analysis of Covariance models. Despite their rather large size (average of 13.8 cm 2 ), our results indicated that RE‐AC achieved almost a 10% higher expected wound closure rate compared to SOC at 12 weeks (8.53% [credible interval: 5.60%–10.7%]). Further, for wounds that did not close, RE‐AC resulted in a 93.6% (credible interval: 147.7%–41.6) improvement in expected Percent Area Reduction over the SOC group at 12 weeks. We noted that on average, SOC wounds stalled or grew larger. In terms of a risk ratio comparing the study group with SOC, we found a 52% benefit in the RE‐AC group (RR = 1.52). The findings suggest that even with larger DFUs, R‐AC is superior to SOC for wound closure and expected Percent Area Reduction by 12 weeks. This benefit likely leads to reduced treatment costs, optimized resource utilization and improved outcomes in the DFU patient population; ultimately resulting in improved patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Open Wound Research, Puyallup, Washington, USA.
- Biostem Technologies, Pompano Beach, Florida, USA.
ORCID-Profile: Robert G Frykberg
Förderung
- BioStem Technologies
Zitieren
APA
Frykberg, R. G., Tunyiswa, Z., & Weston, W. W. (2024). Retention processed placental membrane versus standard of care in treating diabetic foot ulcers. International Wound Journal. https://doi.org/10.1111/iwj.70096
Vancouver
Frykberg RG, Tunyiswa Z, Weston WW. Retention processed placental membrane versus standard of care in treating diabetic foot ulcers. International Wound Journal. 2024. doi:10.1111/iwj.70096
BibTeX
@article{Frykberg2024,
author = {Frykberg, Robert G and Tunyiswa, Zwelithini and Weston, Wendy W},
title = {Retention processed placental membrane versus standard of care in treating diabetic foot ulcers},
journal = {International Wound Journal},
year = {2024},
doi = {10.1111/iwj.70096}
}
EUVIMED